首页> 美国卫生研究院文献>Tissue Engineering. Part A >Prevascularized Microtemplated Fibrin Scaffolds for Cardiac Tissue Engineering Applications
【2h】

Prevascularized Microtemplated Fibrin Scaffolds for Cardiac Tissue Engineering Applications

机译:用于心血管组织工程应用的预血管化微模板纤维蛋白支架

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Myocardial infarction (MI) causes significant cell loss and damage to myocardium. Cell-based therapies for treatment of MI aim to remuscularize the resultant scar tissue, but the majority of transplanted cells do not survive or integrate with the host tissue. Scaffolds can improve cell retention following construct implantation, but often do little to enhance host-graft integration and/or show limited biodegradation. Fibrin is an ideal biomaterial for cardiac tissue engineering as it is a natural, biodegradable polymer that can induce neovascularization, promote cell attachment, and has tunable mechanical properties. Here we describe a novel, high-density microtemplated fibrin scaffold seeded with a tri-cell mixture of cardiomyocytes, endothelial cells (ECs), and fibroblasts to mimic native cardiac tissue in structure and cellular composition to improve cell retention and promote integration with the host tissue. Scaffolds were designed with uniform architecture of parallel 60 μm microchannels surrounded by an interconnected microporous network of 27-μm-diameter pores and mechanical stiffness comparable to native cardiac tissues (70–90kPa). Scaffold degradation was controlled with the addition of Factor XIII (FXIII) and/or protease inhibitor (aprotinin). Unmodified scaffolds had a fast degradation profile both in vitro (19.9%±3.9% stiffness retention after 10 days) and in vivo. Scaffolds treated with FXIII showed an intermediate degradation profile in vitro (45.8%±5.9%), while scaffolds treated with aprotinin or both FXIII and aprotinin showed significantly slowed degradation in vitro (60.9%±5.2% and 76.4%±7.6%, respectively, p<0.05). Acellular aprotinin scaffold myocardial implants showed decreased collagen deposition after 7 days. Unmodified and aprotinin implants could not be located by 14 days, while 2 of 8 FXIII implants were found, but were significantly degraded. Constructs supported seeded cell survival and organization in vitro, promoting EC-lined lumen structure formation in construct channels and colocalization of viable ECs and cardiomyocytes. In addition, constructs promoted extracellular matrix deposition by seeded cells, as shown by collagen staining within construct channels and by significant increases in construct stiffness over 10 days in vitro (209%±32%, p<0.05). The data suggest our fibrin scaffolds are ideally designed to promote graft cell survival and organization, thus improving chances of promoting construct integration with the host tissue upon implantation.
机译:心肌梗塞(MI)导致大量细胞丢失和心肌损伤。用于治疗MI的基于细胞的疗法旨在使所形成的疤痕组织肌肉化,但是大多数移植细胞无法存活或与宿主组织整合。支架可以在构建体植入后改善细胞保留,但通常不能起到增强宿主-移植物整合和/或显示有限的生物降解的作用。纤维蛋白是用于心脏组织工程的理想生物材料,因为它是天然的,可生物降解的聚合物,可以诱导新血管形成,促进细胞附着并具有可调的机械性能。在这里,我们描述了一种新型的高密度微模板化纤维蛋白支架,该支架上植入了心肌细胞,内皮细胞(EC)和成纤维细胞的三细胞混合物,以模仿天然心脏组织的结构和细胞组成,以改善细胞保留力并促进与宿主的整合组织。设计的支架具有平行的60μm微通道的统一结构,周围环绕着直径为27μm的互连微孔网络,其机械刚度可与天然心脏组织(70–90kPa)相比。通过添加因子XIII(FXIII)和/或蛋白酶抑制剂(抑肽酶)来控制支架的降解。未经修饰的支架在体外(10天后19.9%±3.9%的硬度保持率)和体内均具有快速降解特性。 FXIII处理的支架在体外显示出中等程度的降解(45.8%±5.9%),而抑肽酶或FXIII和抑肽酶同时处理的支架在体外降解显着减慢(分别为60.9%±5.2%和76.4%±7.6%)。 p <0.05)。 7天后,脱细胞抑肽酶支架心肌植入物显示胶原沉积减少。未修饰的和抑肽酶植入物在14天之前无法定位,而8个FXIII植入物中有2个被发现,但被严重降解。构建体支持种子细胞的体外存活和组织,促进构建体通道中EC内腔结构的形成以及活EC和心肌细胞的共定位。此外,构建体通过种子细胞促进了细胞外基质的沉积,如构建体通道内的胶原蛋白染色和体外10天构建体刚度的显着增加所表明的那样(209%±32%,p <0.05)。数据表明我们的纤维蛋白支架被理想地设计为促进移植细胞的存活和组织,从而增加了植入后促进构建体与宿主组织整合的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号